The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 8529521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of a 38-kDa high affinity sulfonylurea-binding peptide in insulin-secreting cells and cerebral cortex.

  1994cited by this paper
• Cloning and functional expression of a rat heart KATP channel

  1994cited by this paper
• Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride.

  1994cited by this paper
• Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.

  1994cited by this paper
• The role of ion channels in insulin secretion

  1992cited by this paper
• The sulfonylurea receptor.

  1992cited by this paper
• Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.

  1989cited by this paper
• ATP-sensitive K-channels in HIT T15 β-cells studied by patch-clamp methods, 86Rb efflux and glibenclamide binding

  1989cited by this paper
• Sulfonylurea Receptors, Ion Channels, and Fruit Flies

  1988cited by this paper
• Direct photoaffinity labeling of the putative sulfonylurea receptor in rat β‐cell tumor membranes by [3H]glibenclamide

  1988cited by this paper
• Special pharmacology of the new sulfonylurea glimepiride.

  1988cited by this paper
• The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells.

  1987cited by this paper
• Increased cytosolic calcium. A signal for sulfonylurea-stimulated insulin release from beta cells.

  1987cited by this paper
• Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics.

  1985cited by this paper
• The sulphonylurea receptor may be an ATP-sensitive potassium channel.

  1985cited by this paper
• Interaction of sulfonylurea with the pancreatic B-cell

  1984cited by this paper
• Specific receptors for sulfonylureas in brain and in a beta-cell tumor of the rat.

  1982cited by this paper
• Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties.

  1981cited by this paper

• Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies

  2024cites this paper
• Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

  2021cites this paper
• Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.

  2020cites this paper
• Comparison of Efficacy and Safety of Sulphonylureas-Glimepiride or Gliclazide in Combination with Metformin in Type 2 Diabetes Mellitus Patients

  2020cites this paper
• Mechanisms and characteristics of sulfonylureas and glinides.

  2019cites this paper
• Ameliorative potential of conditioning on ischemia-reperfusion injury in diabetes.

  2018cites this paper
• Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation.

  2017cites this paper
• Glibenclamide Attenuates Blood–Brain Barrier Disruption in Adult Mice after Traumatic Brain Injury

  2017cites this paper
• A study of the role of GATA6 in definitive endoderm specification and beta cell functionality by genome engineering of pluripotent stem cells

  2016cites this paper
• Glibenclamide for the Treatment of Ischemic and Hemorrhagic Stroke

  2015cites this paper
• Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals.

  2015influential citation
• Glibenclamide for the Treatment of Acute CNS Injury

  2013cites this paper
• Transcriptomic Analysis of Insulin-Sensitive Tissues from Anti-Diabetic Drug Treated ZDF Rats, a T2DM Animal Model

  2013cites this paper
• Clinical Relevance of Target Identity and Biology

  2013cites this paper
• Synthesis and antihyperglycemic evaluation of new 2,4-thiazolidinediones having biodynamic aryl sulfonylurea moieties.

  2012cites this paper
• Evaluation of Efficacy and Tolerability of Glimepiride and Metformin Combination: A Multicentric Study in Patients with Type-2 Diabetes Mellitus, Uncontrolled on Monotherapy with Sulfonylurea or Metformin

  2010cites this paper
• Polymeric gene carrier for insulin secreting cells: poly(L-lysine)-g-sulfonylurea for receptor mediated transfection.

  2005cites this paper
• Investigation of structure-activity relationships in a series of glibenclamide analogues.

  2004cites this paper
• The role of glimepiride in the effective management of Type 2 diabetes.

  2004cites this paper
• Rational pharmacotherapy in the diabetic hypertension: analysis‐prescribing patterns in a general hospital in Taiwan

  2004cites this paper
• Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning.

  2002cites this paper
• Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.

  2002cites this paper
• The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.

  2002cites this paper
• Comparative Tolerability of Sulphonylureas in Diabetes Mellitus

  2000cites this paper
• Pathophysiology and pharmacological treatment of insulin resistance.

  2000cites this paper
• The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl

  2000cites this paper
• ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies.

  1999cites this paper
• [Present status in the treatment of type 2 diabetes mellitus. Insulin-secreting agents].

  1999cites this paper
• Glimepiride: Role of a New Sulfonylurea in the Treatment of Type 2 Diabetes Mellitus

  1998cites this paper
• Characterization of sulfonylurea receptors in isolated human pancreatic islets

  1998cites this paper
• Recent advances in potassium channel modulation.

  1997cites this paper
• Beta Cell Response to Oral Glimepiride Administration During and Following a Hyperglycaemic Clamp in NIDDM Patients

  1997influential citation
• Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations

  1996cites this paper
• Mechanisms of the Glycaemic Effects of Sulfonylureas

  1996cites this paper
• The Effect of Glimepiride on Pancreatic β-Cell Function Under Hyperglycaemic Clamp and Hyperinsulinaemic, Euglycaemic Clamp Conditions in Non-Insulin-Dependent Diabetes Mellitus

  1996cites this paper
• Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells.

  1996cites this paper
• Research prospects with benfluorex.

  1996cites this paper